Time trends in the epidemiology and outcome of perianal fistulizing Crohn's disease in a population-based cohort

Autor: Daisy Jonkers, Mariëlle Romberg-Camps, Liekele E. Oostenbrug, K. W. A. Göttgens, Stephanie O. Breukink, Laurents P. S. Stassen, Ad A.M. Masclee, Steven Jeuring, Marieke Pierik, Rosel Sturkenboom
Přispěvatelé: RS: NUTRIM - R2 - Gut-liver homeostasis, Interne Geneeskunde, RS: NUTRIM - R2 - Liver and digestive health, MUMC+: MA AIOS Heelkunde (9), MUMC+: MA Heelkunde (9), RS: SHE - R1 - Research (OvO), Surgery, MUMC+: MA Maag Darm Lever (9)
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Male
CLINICAL-COURSE
Disease
Kaplan-Meier Estimate
Inflammatory bowel disease
Population based cohort
0302 clinical medicine
Crohn Disease
Recurrence
Risk Factors
Epidemiology
Registries
Young adult
Netherlands
Crohn's disease
FISTULAS
Incidence (epidemiology)
Incidence
IN-ANO
Middle Aged
GASTROENTEROLOGY
FIBRIN GLUE
Natural history
Biological Therapy
Treatment Outcome
030220 oncology & carcinogenesis
WORKING PARTY
030211 gastroenterology & hepatology
Female
epidemiology
Adult
medicine.medical_specialty
Risk Assessment
CLASSIFICATION
03 medical and health sciences
Young Adult
Gastrointestinal Agents
Internal medicine
medicine
MANAGEMENT
Humans
Immunologic Factors
Rectal Fistula
population-based cohort
Hepatology
business.industry
Rectovaginal Fistula
perianal fistula
NATURAL-HISTORY
medicine.disease
Surgery
business
INFLAMMATORY-BOWEL-DISEASE
Zdroj: European Journal of Gastroenterology & Hepatology, 29(5), 595-601. LIPPINCOTT WILLIAMS & WILKINS
ISSN: 1473-5687
0954-691X
1991-1998
Popis: Perianal disease is a debilitating condition that frequently occurs in Crohn's disease (CD) patients. It is currently unknown whether its incidence has changed in the era of frequent immunomodulator use and biological availability. We studied the incidence and outcome of perianal and rectovaginal fistulas over the past two decades in our population-based Inflammatory Bowel Disease South-Limburg cohort.All 1162 CD patients registered in the Inflammatory Bowel Disease South-Limburg registry were included. The cumulative probabilities of developing a perianal and rectovaginal fistula were compared between three eras distinguished by the year of CD diagnosis: 1991-1998, 1999-2005 and 2006-2011. Second, clinical risk factors and the risk of fistula recurrence were determined.The cumulative 5-year perianal fistula rate was 14.1% in the 1991-1998 era, 10.4% in the 1999-2005 era and 10.3% in the 2006-2011 era, P=0.70. Colonic disease was associated with an increased risk of developing perianal disease, whereas older age was associated with a decreased risk (both P0.01). Over time, more patients were exposed to immunomodulators or biologicals before fistula diagnosis (18.5 vs. 32.1 vs. 52.1%, respectively, P=0.02) and started biological therapy thereafter (18.6 vs. 34.1 vs. 54.0%, respectively, P0.01). The cumulative 5-year perianal fistula recurrence rate was not significantly different between eras (19.5 vs. 25.5 vs. 33.1%, P=0.28). In contrast, the cumulative 5-year rectovaginal rate attenuated from 5.7% (the 1991-2005 era) to 1.7% (the 2006-2011 era), P=0.01.Over the past two decades, the risk of developing a perianal fistula was stable, as well as its recurrence rate, underlining the lasting need for improving treatment strategies for this invalidating condition.
Databáze: OpenAIRE